Application of CT Contrast Agents in PET-CT Imaging

2010 ◽  
pp. 91-101
Author(s):  
Gerald Antoch ◽  
Patrick Veit ◽  
Andreas Bockisch ◽  
Hilmar Kuehl
2021 ◽  
Vol 13 (9) ◽  
pp. 1674-1684
Author(s):  
Yangfan Zhang ◽  
Yuanyuan Luo ◽  
Xinglei Wu ◽  
Liuqiong Yang ◽  
Dandan Cui ◽  
...  

Traditional computed tomography (CT) contrast agents, such as iodine-containing small molecules (omnipaque), have limitations in some applications. The development of nanotechnology has made it possible to develop CT contrast agents based on this technology. In this study, a large number of surface functional groups of the fifth-generation polyamide-amine dendrimer (P5-NH2) were applied to functionally modify polyethylene glycol (PEG), targeting molecules, or drugs, which were used as the carrier of CT contrast agents. With the help of sodium borohydride (NaBH4), there was a rapid reduction. The fluorescein thiocyanate (FT) and PEG modified with lactobionic acid (PEG-LA) weres connected before gold coating to obtain gold nanoparticles coated with targeted dendrimer (Au(P5-LA)DENPs). In the experiment, the gold nanoparticles were characterized, and the liver cancer nude mouse model was established, so as to analyze the CT imaging performance of the material. Besides, the above was applied in the motor function of children with cerebral palsy, and the improvement effect of CT imaging combined with transcranial magnetic stimulation based on the preparation of nanomaterials on the movement function of children was analyzed and demonstrated with the help of graph theory. The results showed that the average particle size of gold nanoparticles was 1.88 nm. Within the range of 5 °C–50 °C and pH = 4–7, the physical properties of the aqueous solution of this material were stable. What’s more, the cell activity still exceeded 80% when the material concentration reached 2000 nm. The nude mouse model of liver cancer indicated that the CT imaging based on this material enhanced the image contrast effect of the tumor part, and the material had no obvious toxic and side effects. CT imaging based on the preparation of nanomaterials can promote transcranial magnetic stimulation to accelerate the efficiency of brain movement, accelerate the global and local information exchange and integration speed of brain network, thereby improving the movement function of children.


2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Jun Xie ◽  
Zonglang Zhou ◽  
Sihan Ma ◽  
Xian Luo ◽  
Jiajing Liu ◽  
...  

AbstractX-ray computed tomography (CT) has been widely used in clinical practice, and contrast agents such as Iohexol are often used to enhance the contrast of CT imaging between normal and diseased tissue. However, such contrast agents can have some toxicity. Thus, new CT contrast agents are urgently needed. Owing to the high atomic number (Z = 83), low cost, good biological safety, and great X-ray attenuation property (5.74 cm2 kg−1 at 100 keV), bismuth has gained great interest from researchers in the field of nano-sized CT contrast agents. Here, we synthesized BiF3: Ln@PVP nanoparticles (NPs) with an average particle size of about 380 nm. After coating them with polyvinylpyrrolidone (PVP), the BiF3: Ln@PVP NPs possessed good stability and great biocompatibility. Meanwhile, compared with the clinical contrast agent Iohexol, BiF3: Ln@PVP NPs showed superior in vitro CT imaging contrast. Subsequently, after in situ injection with BiF3: Ln@PVP NPs, the CT value of the tumor site after the injection was significantly higher than that before the injection (the CT value of the pre-injection and post-injection was 48.9 HU and 194.58 HU, respectively). The morphology of the gastrointestinal (GI) tract can be clearly observed over time after oral administration of BiF3: Ln@PVP NPs. Finally, the BiF3: Ln@PVP NPs were completely discharged from the GI tract of mice within 48 h of oral administration with no obvious damage to the GI tract. In summary, our easily synthesized BiF3: Ln@PVP NPs can be used as a potential clinical contrast agent and may have broad application prospects in CT imaging.


Radiology ◽  
2003 ◽  
Vol 227 (3) ◽  
pp. 817-824 ◽  
Author(s):  
Yuji Nakamoto ◽  
Bennett B. Chin ◽  
Dara L. Kraitchman ◽  
Leo P. Lawler ◽  
Laura T. Marshall ◽  
...  

2005 ◽  
Vol 44 (S 01) ◽  
pp. S58-S60 ◽  
Author(s):  
W. Mohnike

Summary:PET is being considered a diagnostic commodity in clinical practice worldwide and thus receives increasing attention by health insurances and governmental organizations. In Germany, however, neither PET nor PET/CT are subject to reimbursement. This renders clinical PET and PET/CT imaging a challenge both in a general hospital environment and in private practice. This article describes briefly these challenges, which are not solely related to turf battles and associated costs.


2019 ◽  
Author(s):  
W van Boxtel ◽  
S Lütje ◽  
AC van Engen-van Grunsven ◽  
GW Verhaegh ◽  
JA Schalken ◽  
...  

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2145-P
Author(s):  
ELIZABETH SANCHEZ RANGEL ◽  
JASON BINI ◽  
NABEEL B. NABULSI ◽  
YIYUN HUANG ◽  
KEVAN C. HEROLD ◽  
...  

2007 ◽  
Author(s):  
Stefan Krüger ◽  
S. Pauls ◽  
Felix M. Mottaghy ◽  
Andreas K. Buck ◽  
Hubert Schelzig ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document